Analysis and therapeutic research for growth impairment accompanied with chronic inflammatory syndrome of children as dysregulation of proinflammatory cytokines

全身性幼年特发性关节炎（sJIA）伴发的生长障碍被认为与IL-6（引起全身性炎症的关键细胞因子）抑制软骨细胞增殖和皮质类固醇抑制骨延伸有关。Tocilizumab是一种抗IL-6受体抗体，2008年在日本获得批准，目前主要用于治疗激素难治性或依赖性sJIA。我们调查了45例服用TCZ的sJIA患者的身高和身高增长速度，分析了它们与年龄、性别、疾病持续时间和皮质类固醇暴露等多个因素的相关性，身高标准差评分（HTSDS）与疾病持续时间呈负相关，皮质类固醇减少与身高增长速度改善之间存在强相关性。

Growth impairment accompanied with systemic juvenile idiopathic arthritis (sJIA) is thought to be associated with suppression of proliferation of chondrocyte by IL-6, the key cytokine causing systemic inflammation, and suppression of bone extension by corticosteroid. Tocilizumab, anti-IL-6 receptor antibody, was approved in 2008 in Japan, so now bloadly used as treatment for steroid-refractory or -dependent sJIA. We have investigated height and height velocity of 45 sJIA patient administered with TCZ and analyzed correlation between them and several factors such as age, gender, disease duration and corticosteroid exposure, then inverse correlation between standard deviation score for height (HTSDS) and disease duration and strong correlation between reduction of corticosteroid and improvement of height velocity.